Day: September 27, 2023

VANCOUVER, British Columbia, Sept. 27, 2023 (GLOBE NEWSWIRE) — Looking Glass Labs Ltd. (“LGL” or the “Company”) (NEO: NFTX) (AQSE: NFTX) (OTC: LGSLF) (FRA: H1N) is pleased to announce that it will be consolidating all of the issued and outstanding common shares (“Common Shares”) of the Company on the basis of one (1) post-consolidation Common Share for each seventy-five (75) pre-consolidation Common Shares (the “Consolidation“). The effective date and trading of the Common Shares on a post-Consolidation basis on NEO Exchange Inc., operating as Cboe Canada (the “Exchange”) is expected to be on or about October 6, 2023. The Company’s name and trading symbol will remain unchanged. The new CUSIP number will be 54342Q205 and the ISIN number will be CA54342Q2053. The Consolidation is expected to result in...

Since 1898, The State Bank has been a pillar of financial security and stability for its local Michigan Communities FENTON, Mich., Sept. 27, 2023 (GLOBE NEWSWIRE) — Fentura Financial, Inc. (OTCQX: FETM) is proud to celebrate the 125th anniversary of The State Bank. The State Bank has been a part of the Fenton community since 1898. H.B. Latourette, a long-time banker in the area, and four other prominent citizens organized the Commercial Savings Bank of Fenton. They sought to serve the needs of their neighbors and friends thereby establishing a foundation of trust, a relationship that still exists today. From the Great Depression to the Great Recession and beyond, The State Bank has held tight to its community values. Through resilience, integrity and innovation, the bank has helped businesses and families meet their needs and build...

Omaha, NE, Sept. 27, 2023 (GLOBE NEWSWIRE) — FitLife Brands, Inc. (“FitLife” or the “Company”) (Nasdaq: FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced that the US Bankruptcy Court for the District of Nevada has approved FitLife’s acquisition of substantially all of the assets of MusclePharm Corporation under Section 363 of the US Bankruptcy Code. Highlights of the transaction are as follows:The all-cash transaction, with no shares being issued by FitLife, is expected to be highly accretive to existing shareholders once all transaction-related costs (anticipated to be approximately $500,000) have been expensed. The purchase price of $18.5 million, which is subject to customary adjustments, will be funded using cash on hand and the proceeds of a new committed $10 million...

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) — Ponce Financial Group, Inc., (the “Company”) (NASDAQ: PDLB), the holding company for Ponce Bank (the “Bank”), today announced that the Bank received approval for a grant in the amount of $451,025 as part of the Bank Enterprise Award Program from the Community Development Financial Institutions (“CDFI”). Awards under the Bank Enterprise Award Program are subject to the program terms and must be used for qualified activities, which include providing loans, investments and financial services to residents and businesses in distressed communities. The Bank also announced today that it has received the previously announced $3.7 million in cash that was granted from the U.S. Treasury as part of the Community Development Financial Institutions (“CDFI”) Equitable Recovery...

TAMPA, Fla., Sept. 27, 2023 (GLOBE NEWSWIRE) — Better Choice Company, Inc. (NYSE American: BTTR) (“Better Choice” or the “Company”), a pet health and wellness company, today announced that it received a Notice (the “Notice”) on September 21, 2023 from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the continued listing standards as set forth in Section 1003(f)(v) of the NYSE American Company Guide (“Company Guide”). The Notice stated that because the Company’s common stock had been trading for a low price per share for a substantial period of time, the Company was not in compliance with Section 1003(f)(v) of the Company Guide. The NYSE American staff (the “Staff”) determined that the Company’s continued listing is predicated on effecting a reverse stock split of its common stock or...

BRYAN, Texas and SAN DIEGO, Sept. 27, 2023 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today the filing of its annual report on Form 10-K with the United States Securities and Exchange Commission (“SEC”) for the fiscal year ended June 30, 2023. Revenues for the fiscal year ended June 30, 2023 were $nil, compared to $1.9 million in fiscal 2022. Total operating expenses, not including the loss from discontinued operations, were $29.3 million in fiscal 2023, a 7% decrease from $31.6 million in fiscal 2022. iBio’s consolidated net loss for the fiscal year ended June 30, 2023 was $65.0 million, an increased loss of $14.6 million compared to 2022, due primarily to increased loss from discontinued operations. iBio held cash...

BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) — PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that it will be presenting at the 28th Annual Congress of the World Muscle Society, being held October 3-7 in Charleston, South Carolina. Details of the presentations can be found below: 28th Annual Congress of the World Muscle Society, being held October 3-7 in Charleston, South Carolina Title: Phase 1 Study of PGN-EDO51 Demonstrates Tolerability, Delivery, and High Levels of Exon Skipping for Treatment of Duchenne Muscular Dystrophy (DMD)Poster Number: P44Location: Ballroom A-CDate & Time: October 4th at 2:30-3:30pm EDTPresenter: Michelle Mellion,...

ROCKVILLE, Md., Sept. 27, 2023 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it will host and webcast a Research & Development (R&D) Day on Wednesday, October 18, 2023. During the event, members of Supernus’ senior management team will provide an overview of the Company’s pipeline, with emphasis on SPN-820/821, SPN-817 and new clinical candidates from the Supernus’s discovery program. In addition, a key opinion leader will share his perspectives on the current treatment paradigms, unmet medical needs and the Company’s clinical development programs. Presentation Date: Wednesday, October 18, 2023Time: 8:00 a.m. ET (registration); 8:30 a.m....

BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will host a R&D Day on Monday, October 2, at 9:00 a.m. EDT, virtually and in person in New York City. During the event, Praxis’ management team will review progress from its pipeline programs, including the anticipated initiation of the Phase 3 program for ulixacaltamide in essential tremor and advances in its clinical epilepsy assets. Praxis’ management team will be joined by key opinion leaders in Movement Disorders and Epilepsy, including Alberto J. Espay, M.D., MSc, FAAN, FANA, Professor and Endowed Chair...